Publications and Presentations. The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, without the prior review by and the approval of the JSC in accordance with Section 2.1. Each Party shall provide to the JSC the opportunity to review any of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) which relate to the Research Program, the Development of a Candidate or the Commercialization of a Product at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC within such [*****] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC reasonably believes is patentable. Once such abstracts, manuscripts or presentations have been reviewed by the JSC, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission for publication. Each Party also shall have the right to require that its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.
Publications and Presentations. For purposes of this Agreement, “Scientific Publication” means any scientific publication or medical communication regarding Study results in any form that is intended for disclosure to third parties, including, without limitation, manuscripts, abstracts, posters, slides or other materials used for presentations.
Publications and Presentations. Please list the journal article publications based on the findings of this work. Please indicate their status (planned, in draft, under review, submitted, in-press, published). Please indicate the conferences to which you have submitted abstracts and their status (i.e. accepted, oral presentation / poster presentation) Please list any invitations for oral presentations where you have or plan to present the findings of this research.
Publications and Presentations. Without Pfizer's written prior approval, Supplier shall not:
a) make any presentation, public announcement, or publication of any kind relating to any and all matters arising out of or in connection with this PO, including this PO itself, or
b) use in any matter whatsoever any trademarks, logos, service marks, trade names, corporate names, proprietary logos, indicia or other business identifiers of any sort of Pfizer.
Publications and Presentations. 4.1 Each Party will have the right to publish or give public presentations of the Common Results (as defined in § 5.1) but shall be subject to the prior written agreement of all of the other Parties. The details and timing of the decision to publish or give a presentation and the extent and content of the publication or presentation shall also be agreed beforehand, in writing between all the Parties (see §§ 4.3 and 4.4). Any other publication or presentation of the Common Results is strictly forbidden to the Parties. For the avoidance of doubt, unless otherwise agreed in writing by the concerned Parties, no publication or presentation of any Party’s Background IP and/or Own Common Results is permitted, directly as indirectly, in any manner whatsoever.
4.2 All publications and presentations on the Common Results shall be made under the joint authorship of the Parties in compliance with the rules of good scientific practice. Furthermore, all publications and presentations shall include that the Research Project, and more generally, this Agreement, is covered by a grant from the Xxxxx Xxxxxxxxxx- Xxxxx COFUND Programme “InnovaXN” (contract number 847439 with the European Commission). Each submission for publication shall be signed by the Supervisors referred to in § 2.5. Each presentation shall contain written text that acknowledges and mentions the joint authorship and the contribution made by each of the Parties in compliance with the rules of good scientific practice. For the sole need of the present article 4.2, each Party consents to the others, in the terms and conditions hereunder convened, a free and non-exclusive right of exploitation of its name and logo, for the validity period of this Agreement. This right shall cease immediately and automatically in case of termination of this Agreement, whatever the cause or the date. Prior termination against a/several Party(ies) shall however not call into question the survival of this right for the non- concerned Parties, which remains in force, until the agreed contractual term.
4.3 The Party wishing to publish shall notify the other Parties by submitting a copy of the manuscript for review and comment, so as to arrive at least 45 (forty five) calendar days before the due date for submission for publication. The Party wishing to give a presentation shall notify the other Parties by submitting for review and comment a copy of the description of the content of the presentation and a copy of any visual aids to ...
Publications and Presentations. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to be published or presented, the results of or information pertaining to the Research Program or any Development Plan for, or Co-Development of, a Fully-Exercised Co-Developed Product, without the prior review by and approval of an authorized representative of the other Party. Further, ARCHEMIX shall not publish or present, or allow to be published or presented any information pertaining to (a) Development of a Product that is not a Fully-Exercised Co-Developed Product or (b) any Commercialization activities, without the prior review by and approval of an authorized Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. representative of ELAN. Except with respect to Fully-Exercised Co-Developed Products, ELAN shall be free to publish and present results of Development, including details regarding the relevant Lead Compounds, Clinical Candidates and/or Products, in accordance with the remainder of this Section 6.3. The Parties acknowledge that scientific publications and public presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Accordingly, each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or public presentations (including, without limitation, information to be presented verbally to the public) that relate to the Research Program or any Co-Development Program at least [***] days prior to its intended public presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [***] day period, not to submit such abstract or manuscript for publication or to make such public presentation until the other Party is given up to [***] days from the date of such written request to seek appropriate patent protection for any material in such intended publication or public presentation that it reasonably believes may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by each Party, the same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submi...
Publications and Presentations. The publication and presentation of Study Data and Sample Data, including provisions regarding the Confidential Information of a Party contained in such a disclosure, is governed by Section 8.2.
Publications and Presentations. Sponsor acknowledges that Rice and the Project Team members shall have the right to publish or otherwise publicly disclose at academic and professional conferences and other meetings the results of the Engineering Design Project, subject to the following limitations. A draft copy of the proposed publication or public presentation (except for student theses and dissertations) shall be provided to Sponsor for its review at least 30 days prior to submission for publication or public presentation. During such 30 day period, Sponsor may request that Rice delay the proposed publication or public presentation for up to an additional 30 days to allow for patent or copyright filings or other matters related to the protection of Intellectual Property. In addition, Sponsor may suggest changes to the proposed publication or public presentation, but the author shall retain final authority; provided, however, that the author shall be obligated to remove any Confidential Information furnished by Sponsor pursuant to Section 6 below. Notwithstanding anything in this Agreement to the contrary, copyrights in publications, public presentations and other scholarly writings shall be owned by their respective authors.
Publications and Presentations. The SC will coordinate the plans of the Parties regarding planned publication in the Territory of Data or other clinical or pre-clinical results relating to Products into a single schedule that will be shared with the Parties. With respect to publication in any academic journal, authorship of any publication shall be subject to the obligations of confidentiality herein and determined based on the accepted standards used in peer-reviewed, academic journals at the time of the proposed publication. Notwithstanding the forgoing, each Party recognizes the mutual interest in obtaining valid Patent protection and in protecting business interests and trade secret information. Consequently, except for disclosures permitted pursuant to Article 12.2, if either Party, its employees or consultants wishes to publish or present to any Third Party, results of the Development work, or any research results, or any Data or other clinical information about a Product being Developed or Commercialized pursuant to this Agreement, it shall deliver to the other Party a copy of the proposed written publication or an outline of an oral disclosure as soon as practicable prior to submission for publication or presentation. The reviewing Party shall notify the other Party promptly after receipt of such proposed publication whether such draft publication contains (a) Confidential Information of the reviewing Party, or (b) information that if published would have an adverse effect on a Patent or a Party. The reviewing Party shall have the right to (i) propose modifications to the publication or presentation for Patent reasons, trade secret reasons, confidentiality reasons or business reasons or (ii) request a reasonable delay in publication or presentation in order to protect patentable information. If the reviewing Party requests a delay to protect patentable information, the publishing Party shall delay submission or presentation for a period not to exceed thirty (30) days to enable Patent applications protecting each Party’s rights in such information to be filed in accordance with the terms of this Agreement. Upon expiration of such thirty (30) days, the publishing Party shall be free to proceed with the publication or presentation. If the reviewing Party reasonably requests modifications to the publication or presentation to prevent disclosure of material trade secret or proprietary business information, the publishing Party shall edit such publication to prevent the disclosure of s...
Publications and Presentations. Proposals for specific analyses made by the DAC Working Groups will have a limited period of protected time (9-12 months) from the time of Program Data receipt, in which similar proposals from other investigators are rejected. If after this period no results have been shared with the SC by the DAC Working Group, a collaboration might be proposed between the DAC Working Group and the other investigators with a similar proposal. • In the title of the Publications or Presentations it must be made clear that the Program is sponsored by BIG. • Prior to submission to the journal/conference of a proposed Publication or Presentation, the first author shall share the final draft with the SC coordinator at BIG Headquarters (HQ) (xxxxxx.xxxxx@xxxxxxxxxxxx.xxx) for review by the SC. • The SC shall review and approve the material to be published or presented within ten (10) working days for a Publication and five (5) working days for a Presentation.
